Few research peptides get as much attention as BPC-157. Online, it is often called a "healing peptide," credited with speeding recovery from tendon tears, calming an irritated gut and even protecting the brain. Behind that reputation is a large body of animal research, most of it from a single lab in Croatia.
This guide walks through what BPC-157 is, how it is thought to work, what the research does and doesn't show, the doses used in studies, and where it stands legally after the FDA's July 2026 advisory vote.
What Is BPC-157?
BPC-157 stands for Body Protection Compound-157. It is a synthetic pentadecapeptide, a chain of 15 amino acids: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its sequence comes from a larger protective protein found in human gastric juice. BPC-157 itself is made in a lab.
Peptides are short chains of amino acids, generally between 2 and 50 units long. The body makes thousands of its own, including hormones such as insulin and signaling molecules involved in repair. Synthetic peptides like BPC-157 are built to copy or adapt those natural sequences.
Its Role in the Gut
BPC-157 was first studied for stomach protection. It is unusually stable in gastric acid, which most peptides are not. In rodent studies it protected the stomach and intestinal lining from ulcers, alcohol, NSAID painkillers and other injuries. Researchers later found its effects in animals reached well beyond the gut.
Areas of Research
Animal and cell studies have looked at BPC-157 for:
-
Tendon, ligament and muscle repair
-
Bone healing
-
Gut lining protection and inflammatory bowel conditions
-
Nerve and brain injury
-
Skin wound healing
-
Blood vessel protection
How It Is Supplied and Given in Studies
BPC-157 is typically supplied as a freeze-dried (lyophilized) powder that is dissolved in sterile liquid before use. Animal studies have given it by injection into the abdomen, under the skin or into muscle, by mouth in drinking water, and on the skin. The few human studies have used IV infusion, injection into the knee and instillation into the bladder.
The Science Behind BPC-157
No single receptor for BPC-157 has been found. Instead, research points to several overlapping actions.
Blood Vessel Growth
Injured tissue needs blood flow to heal. In animal studies, BPC-157 promoted angiogenesis, the growth of new blood vessels, in damaged areas. It appears to do this partly by increasing signaling through VEGFR2, a key receptor for vascular growth.
Growth Factor Signaling
BPC-157 has been linked to higher activity of growth-related signals in injured tissue. In tendon cells, it increased expression of the growth hormone receptor and activated the FAK-paxillin pathway, which controls how cells attach, spread and migrate.
The Nitric Oxide System
Nitric oxide relaxes blood vessels and helps regulate blood flow, immune activity and repair. Sikiric's group has proposed that BPC-157 acts as a modulator of the nitric oxide system, helping balance it in both directions depending on the injury model.
Inflammation
In animal models, BPC-157 reduced markers of inflammation and the tissue damage that comes with it. Controlled inflammation is part of normal healing, so the goal is balance rather than complete suppression.
Is BPC-157 a Growth Hormone Secretagogue?
No. This is a common mix-up online. Growth hormone secretagogues, such as GHRP-6, ipamorelin and CJC-1295, signal the pituitary gland to release growth hormone. BPC-157 has not been shown to do that.
The confusion comes from a 2014 cell study showing BPC-157 increased the number of growth hormone receptors on tendon cells. More receptors could make tissue more responsive to the growth hormone already present, which may help explain its effects on tendon healing. That is a different mechanism from raising growth hormone levels.
Potential Benefits for Healing
Everything in this section comes from animal and cell research unless noted.
Muscle, Tendon and Ligament Repair
This is the most studied area. In rats, BPC-157 improved healing of cut or torn Achilles tendons, ligaments and muscles, with better strength and function. In tendon cell cultures, it increased the outgrowth and migration of tendon fibroblasts in a dose-dependent way.
Gut Health
Across many rodent models, BPC-157 protected against and healed stomach ulcers, intestinal damage, fistulas and colitis. This gut-focused research is why ulcerative colitis was the nominated use in the FDA's 2026 review.
Nerve and Brain Protection
In a rat model of stroke, BPC-157 reduced both early and delayed nerve damage in the hippocampus and improved recovery on behavioral tests. Other rodent studies report benefits after spinal cord and peripheral nerve injury.
Wound and Bone Healing
Animal studies report faster closure of skin wounds and burns, and improved healing of bone defects.
BPC-157 and the Phases of Injury Recovery
Tissue heals in three overlapping phases. Animal research suggests BPC-157 may act on each one.
| Healing phase | What happens | What animal studies suggest about BPC-157 |
|---|---|---|
| Inflammatory | Immune cells clear damage and send repair signals | Helps keep inflammation from becoming excessive |
| Proliferative | New blood vessels and tissue form; fibroblasts lay down collagen | Promotes blood vessel growth and fibroblast migration |
| Remodeling | Collagen fibers align and the tissue strengthens | Improved tissue organization and strength in tendon models |
Whether these effects carry over to human injuries has not been tested in controlled trials.
What Human Studies Show
Human evidence is much thinner than the animal record.
| Study | Participants | What it tested | Main limitation |
|---|---|---|---|
| Lee & Burgess, 2025 | 2 healthy adults | IV infusion of 10 mg, then 20 mg; no adverse events | Two people, safety only |
| Lee et al., 2024 | 12 women with interstitial cystitis | 10 mg into the bladder; symptom improvement reported | No control group |
| Lee & Padgett, 2021 | Small group with chronic knee pain | Injection into the knee, alone or with thymosin beta-4 | Retrospective, subjective outcomes |
| PLIVA trials, early 2000s | Patients with ulcerative colitis | Enema formulation | Published only as abstracts |
In its July 2026 review, the FDA found no human study using the oral, injected, nasal or transdermal routes most people use.
Potential Side Effects and Risks
Reactions
With any injected peptide, injection-site redness, itching or swelling and, rarely, allergic reactions are possible. Anyone who develops a rash, swelling or trouble breathing should stop and seek medical care.
Growth Signaling and Tumors
BPC-157 promotes blood vessel growth and growth factor signaling. Some researchers have raised a theoretical concern that this could support the growth of existing tumors. This has not been studied in humans, and people with a history of cancer should be especially cautious.
Hormonal and Medical Conditions
BPC-157 is not known to change hormone levels directly. Because it affects growth-related signaling, people with hormone-related conditions or on hormone therapy should talk to a physician first.
Product Quality
Products sold outside regulated pharmacies can vary in purity, content and sterility. In 2026, the FDA noted it could not yet define BPC-157 precisely enough to set quality standards.
Long-term human safety is unknown.
How BPC-157 Compares With Other Recovery Peptides
| BPC-157 | TB-500 | GH secretagogues (CJC-1295, ipamorelin) | |
|---|---|---|---|
| Main proposed action | Blood vessel growth, NO system, tendon cell activity | Cell migration via actin binding | Raise growth hormone release from the pituitary |
| Affects GH levels | Not shown | Not shown | Yes |
| Human data | 3 small pilot studies | None for the fragment | Limited |
| WADA status | Prohibited | Prohibited | Prohibited |
No controlled study has tested BPC-157 in combination with any of these.
Legal Status and Availability
Around the World
BPC-157 is not approved as a medicine in any country. It is named on the World Anti-Doping Code's prohibited list and banned at all times for tested athletes.
In the United States
-
2023: the FDA placed BPC-157 on its Category 2 list of bulk substances with safety concerns, blocking compounding pharmacies from preparing it.
-
April 2026: it was removed from Category 2 after its nomination was withdrawn.
-
July 23, 2026: the FDA's Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend adding BPC-157 to the list of substances compounding pharmacies may use, for ulcerative colitis. FDA's own reviewers had recommended against it.
-
Now: the vote is advisory. Compounding is not permitted until the FDA completes formal rulemaking.
What Comes Next
If the FDA follows the committee's recommendation, physicians could eventually prescribe compounded BPC-157 through licensed pharmacies. That would still not make it an FDA-approved drug. Approval would require controlled clinical trials, which have not yet been done.
Conclusion
BPC-157 has one of the most consistent records of benefit in animal research of any peptide, especially for tendons, ligaments and the gut. Its proposed mechanisms, from blood vessel growth to tendon cell signaling, give a plausible explanation for those results.
What it lacks is human evidence. Three small pilot studies are not enough to establish whether it works in people, at what dose or how safely over the long term. The 2026 regulatory shift may open the door to more structured use and, hopefully, the controlled trials needed to answer those questions.
Disclaimer
This article is for educational and informational purposes only. BPC-157 is not approved by the FDA or any regulatory body. Doses described come from published research and are not recommendations for use. Nothing here is medical advice. The Peptide Library is operated in connection with ZenoPeps. Research products are not intended for human consumption.
References
-
Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. PubMed 20877363.
-
Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 2011. PubMed 21030672.
-
Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules, 2014. PubMed 25415472.
-
Gwyer D, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PubMed 30915550.
-
BPC-157 in a rat model of stroke, PMC8504390.
-
Lee E, Burgess J. Safety of intravenous infusion of BPC-157 in humans: a pilot study. Alternative Therapies in Health and Medicine, 2025. PMID 40131143.
-
Lee E, Padgett B. Intra-articular injection of BPC-157 for multiple types of knee pain. Alternative Therapies in Health and Medicine, 2021.
-
FDA advisory committee vote coverage, July 2026.